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Abstract
 
Interleukin (IL)-4 and IL-12 together with T cell receptor (TCR) engagement are crucial for
the differentiation of CD4
 
1
 
 T cells into T helper (Th)2 or Th1 cells, respectively. Although
IL-4 receptors (IL-4Rs) but not IL-12Rs are expressed on naive CD4
 
1
 
 T cells, IL-4 has no ap-
parent advantage over IL-12 in driving naive T cell differentiation when the cells are primed
with both IL-4 and IL-12 in vitro. It was found that IL-4–induced phosphorylation of Janus ki-
nases 1 and 3, IL-4R
 
a
 
, signal transducer and activator of transcription 6, and insulin receptor
substrate 2 was strikingly but transiently inhibited by TCR ligation both in conventional and
TCR transgenic T cells. TCR engagement also blocked the expression of an IL-4–inducible
gene. Signals induced by other cytokines, including IL-2, IL-6, and interferon 
 
a
 
, but not by
insulin-like growth factor 1, were also blocked by TCR engagement. The capacity of various
inhibitors to reverse TCR-mediated inhibition of IL-4 signaling suggested that activation of
the Ras–mitogen-activated protein kinase pathway and of the calcineurin pathway contribute
 
to desensitizing IL-4R. IL-4 responsiveness returned at about the time (
 
z
 
12 h) that IL-12–
mediated signaling was first observed. Thus, through different mechanisms, neither IL-4R nor
IL-12R has any clear advantage in polarizing cells; rather, the availability of cytokine is proba-
bly the limiting factor in this process.
Key words: cytokine signal transduction • T cell activation and differentiation • cross-talk • 
calcineurin • mitogen-activated protein kinase
 
Introduction
 
IL-4 plays a central role in regulating the behavior of he-
matopoietic cells. It controls the specificity of Ig class
switching in B cells and Th2 polarization in T cells (1). IL-4
can act as a costimulant of lymphocyte growth and can pre-
vent apoptosis (2, 3). These functions of IL-4 are achieved
through IL-4R–mediated signal transduction followed by
specific gene expression (4).
IL-4 heterodimerizes the IL-4R
 
a
 
 chain and the IL-2R
 
g
 
chain (
 
g
 
c)
 
1
 
; 
 
g
 
c is also shared by cytokine receptors for IL-2,
IL-7, IL-9, and IL-15 (5). The nonreceptor tyrosine kinases
Janus kinase (Jak)1 and Jak3, constitutively associated with
IL-4R
 
a
 
 and 
 
g
 
c, respectively (6–8), become activated after
IL-4 binding to its receptor and phosphorylate some or all
of the conserved tyrosines of IL-4R
 
a
 
. These phosphoty-
rosines and the immediately surrounding amino acids
within IL-4R
 
a
 
 provide docking sites for the phosphoty-
rosine binding (PTB) domain proteins insulin receptor sub-
strate (IRS)-1/2 (9–11), Shc (12), and IL-4R interacting
protein (FRIP) (13), and for signal transducer and activator
of transcription (Stat)6 (4, 14).
Two major IL-4–signaling pathways are mediated by the
PTB domain proteins and Stat6, respectively (15, 16). The
former is mainly important for cell proliferation and cell
survival (17). The genes that are regulated by IL-4 through
IRS-2 and other PTB domain adapters are unknown,
whereas Stat6 is directly responsible for inducing expres-
sion of a set of IL-4–inducible genes (18–21). Although the
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TCR Ligation Inhibits IL-4 Signaling
 
role of IRS-2 and other PTB domain proteins during Th2
cell differentiation is unclear, Stat6 plays a critical role in
driving this process (22–25).
Ligation of TCRs by antigen–MHC complexes on
APCs triggers T cell activation (26). A second signal, medi-
ated by the interaction of CD80/86 and CD28 or other
molecules, is required for full activation (27). TCR ligation
induces two major signal transduction pathways, the pro-
tein kinase C (PKC)–mitogen-activated protein kinase
(MAPK) pathway and the calcium-dependent calcineurin-
mediated pathway (28).
The differentiation of naive T cells in the Th1 or Th2
direction requires both TCR-mediated and cytokine (IL-
12 or IL-4)-mediated signals. It is known that, in the pres-
ence of TCR-mediated signals, IL-4 activates Stat6, leading
to the development of a Th2 response (22–25), whereas
IL-12 activates Stat4 and causes development of a Th1 re-
sponse (29–31). How the signals from the TCR and the
cytokine receptors are integrated is not well understood.
IL-4–mediated activation of Stat6 may antagonize the
capacity of IL-12 to drive Th1 differentiation (32, 33). One
aspect of this inhibition involves downregulating IL-
12R
 
b
 
2 expression (33, 34). Interestingly, IL-4 can induce
strong signals in naive T cells whereas IL-12 fails to do so
until its receptor is induced by TCR engagement for cer-
tain period of time. Despite this, IL-4 has no apparent ad-
vantage over IL-12 in driving T cell differentiation when
both of them are present. To attempt to understand this,
the early signaling events induced by IL-4 or IL-12 during
T cell activation were studied. It was found that although
IL-4 induced strong signals in naive T cells, this signal was
strikingly but transiently inhibited by TCR engagement.
Responsiveness returned after 12 h of TCR ligation at a
time when the activated cells also respond to IL-12.
 
Materials and Methods
 
Mice and T Cell Purification.
 
8–12-wk-old BALB/c mice,
B10.A mice, and TCR transgenic 5CC7/Rag2
 
2
 
/
 
2
 
 mice were
obtained from the Frederick Cancer Research and Development
Center (Frederick, MD). Spleen T cells were purified through
mouse T cell enrichment columns (R&D Systems). Naive CD4
 
1
 
T cells were prepared as follows: lymph node cells were depleted
of CD8
 
1
 
 cells, B220
 
1
 
 cells, and IA
 
d
 
1
 
 cells by negative selection
using FITC-labeled anti-CD8, anti-B220, and anti-IA
 
d
 
 (BD
PharMingen) plus anti–fluorescein-conjugated magnetic beads
(PerSeptive Biosystems). The purified CD4
 
1
 
 T cells were then
centrifuged on a discontinuous 50, 60, and 70% Percoll gradient.
Cells with a density of 
 
.
 
60% were collected and used for direct
stimulation or priming. The purity of CD4
 
1
 
 T cells after purifica-
tion is usually 
 
z
 
98%. Of these, 90% are CD44
 
low
 
 and CD62L
 
high
 
.
For the signaling experiments using soluble anti-CD3 or antigen,
lymph node and spleen cells from BALB/c mice or lymph node
cells from 5CC7/Rag2
 
2
 
/
 
2
 
 mice and T cell–depleted spleen cells
from B10.A mice were pooled and stimulated with soluble anti-
CD3 or pigeon cytochrome C (PCC) peptide for 6 h. CD4
 
1
 
 T
cells were purified by positive selection (through an automatic
MACS machine) using anti–mouse CD4 (L3T4) MicroBeads
(Miltenyi Biotec). Purified CD4
 
1
 
 T cells were then stimulated by
IL-4 (1,000 U/ml) for 20 min and total cell lysates were made. T
 
cell–depleted APCs were prepared by incubating spleen cells with
anti-Thy1.2 and rabbit complement (Cedarlane Laboratories
Limited) at 37
 
8
 
C for 45 min, and then irradiated at 3,000 rads.
 
Cell Culture and Priming.
 
Purified T cells or naive CD4
 
1
 
 T
cells were treated with plate-bound anti-CD3 (2C11, 3 
 
m
 
g/ml;
Harlan) and anti-CD28 (3 
 
m
 
g/ml; Harlan) in complete RPMI
1640 for various times. In some experiments, anti–IL-4 (11B11)
or inhibitors were added to the culture during TCR engagement.
At the end of TCR treatment, cells were washed and incubated
with IL-4 (1,000 U/ml) for 20 min. MAPK kinase (MEK) inhib-
itor U0126 was purchased from Promega. PMA, ionomycin,
PKC inhibitor (GF109203X), calcineurin inhibitors (cyclosporin
A [CsA] and FK506), and protein synthesis inhibitor (cyclohex-
imide) were purchased from Calbiochem. To study in vitro
priming for cytokine expression, 10
 
6
 
 naive CD4
 
1
 
 BALB/c T
cells were cocultured with 10
 
7
 
 irradiated T cell–depleted spleen
cells in the presence of anti-CD3 (3 
 
m
 
g/ml), anti-CD28 (3 
 
m
 
g/
ml), IL-2 (10 U/ml), and different combinations of anti–IL-4
(11B11, 10 
 
m
 
g/mL), IL-4 (1,000 U/ml), anti–IL-12 (10 
 
m
 
g/ml),
and IL-12 (10 ng/ml) for 20 h. Cells were then washed and stim-
ulated with anti-CD3, anti-CD28, IL-2, IL-4, and IL-12 for an
additional 3 d. After incubation in IL-2 for an additional 3 d, cells
were restimulated with plate-bound anti-CD3 and anti-CD28 for
6 h; monensin (2 
 
m
 
M) was present during the last 4 h. Cells were
harvested for intracellular staining for IFN-
 
g
 
 and IL-4 expression.
 
Immunoprecipitation and Western Blotting.
 
Cytokine-treated
cells (10
 
7
 
 per sample) were harvested and lysed with 1 ml lysis
buffer (50 mM Hepes, pH 7.0, 0.5% NP-40, 5 mM EDTA, 50 mM
sodium chloride, 10 mM sodium pyrophosphate, and 50 mM
sodium fluoride), freshly supplemented with inhibitors (1 mM so-
dium orthovanadate, 1 mM PMSF, and 10 
 
m
 
g/ml each of
aprotinin, leupeptin, and pepstatin), on ice for 20 min. After cen-
trifugation at 12,000 rpm for 15 min, supernatants were incu-
bated with 2–3 
 
m
 
g antibody for 1 h on ice and precipitated with
protein G–agarose (Pierce Chemical Co.) at 4
 
8
 
C overnight on a
rocker. The complexes were then washed three times with lysis
buffer and eluted with 2
 
3
 
 SDS-PAGE loading buffer. The eluted
samples were separated in 8 or 12% premade acrylamide gels
(Novex) and transferred onto Immobilon-P membranes (Milli-
pore). Membranes were then probed with specific antibodies fol-
lowed by horseradish peroxidase–labeled secondary antibodies
(Amersham Pharmacia Biotech) and visualized with Supersignal
West Dura extended duration substrate (Pierce Chemical Co.).
For some experiments, the probed membranes were stripped
with stripping buffer (2% SDS, 62.5 mM Tris-HCl, pH 6.8, and
100 mM 2-ME) at 60
 
8
 
C for 30 min and then reprobed with a
second antibody. Anti-Jak1 and anti-Jak3 antiserum for immuno-
precipitation were purchased from Upstate Biotechnology (cat.
nos. 06-272 and 06-342). Anti-Jak1 for Western blot was pur-
chased from Santa Cruz Biotechnology, Inc. (cat. no. sc-277) and
monoclonal anti-Jak3 for Western blot was from Upstate Bio-
technology (cat. no. 05-406). Anti-Stat6, anti-Stat4, anti-Stat3,
and anti-Stat5b were purchased from R&D Systems. Anti–phos-
phorylated tyrosine 4G10 and anti–IRS-2 were from Upstate
Biotechnology. Anti–IL-4R
 
a
 
 (M2) for immunoprecipitation was
a gift of Immunex Corporation (Seattle, WA). Anti–IL-4R
 
a
 
,
anti–p-ERK, and anti–ERK-1 for Western blot were purchased
from Santa Cruz Biotechnology, Inc.
 
Flow Cytometry Analysis and Intracellular Staining.
 
For IL-4R
 
a
 
chain or 
 
g
 
c chain staining, lymph node cells from 5CC7/Rag2
 
2
 
/
 
2
 
mice were cocultured with T cell–depleted spleen cells in the
presence of 0 or 1 
 
m
 
M PCC for 6 h, and stained with either anti–
IL-4R (M1; Immunex), anti-
 
g
 
c (18361D; BD PharMingen), or 
1127
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rat isotype control for 30 min in FACS
 
®
 
 buffer (PBS with 3%
FCS). The cells were then washed three times in FACS
 
®
 
 buffer
and incubated with biotin-labeled anti–rat IgG. After further
washing, they were stained with streptavidin-PE and FITC-
labeled anti-CD4. For intracellular staining, cells were restimu-
lated with plate-bound anti-CD3 and anti-CD28 for 6 h in the
presence of monensin (2 
 
m
 
M) during the last 4 h. Harvested sam-
ples were fixed with 4% formaldehyde, washed, and permeabi-
lized in 0.5% saponin/1% BSA in PBS before staining with anti–
IL-4–PE and anti–IFN-
 
g
 
–FITC (BD PharMingen). Samples
were analyzed on a FACScan™ (Becton Dickinson).
 
Semiquantitative Reverse Transcription PCR.
 
Purified naive
CD4
 
1
 
 T cells were stimulated with IL-4 (1,000 U/ml) in the ab-
sence or presence of plate-bound anti-CD3/anti-CD28 for 4 h.
Total RNA was isolated using TRIzol (GIBCO BRL) and first
strand cDNAs were made using the SuperScript™ Preamplifica-
tion System (GIBCO BRL) according to the manufacturer’s pro-
tocol. Semiquantitative PCR was carried out in a GeneAmp
PCR system 9700 (PerkinElmer) using Platinum PCR SuperMix
(GIBCO BRL) by a serial dilution of the cDNA templates. The
primers for IL-4R
 
a
 
 were AATGTGACCTACAAGGAACC
and ATGGCCACCAAGGGACTGCG. The primers for 
 
b
 
-actin
were GATGACGATATCGCTGCGCTG and TACGACCA-
GAGGCATACAGG.
 
Results
 
TCR Ligation Transiently Downregulates IL-4 Signaling.
 
Stat6 and IRS-2, two major IL-4R signaling molecules (4,
15, 16), are promptly tyrosine phosphorylated in response
to IL-4 treatment of BALB/c splenic T (Fig. 1, A and B)
and CD4
 
1
 
 lymph node T (Fig. 1, C and D) cells. How-
ever, if the cells were stimulated with plate-bound anti-
CD3 plus anti-CD28 for 6 h, phosphorylation of both
Stat6 and IRS-2 is dramatically inhibited; no change in the
amounts of Stat6 or IRS-2 was observed, although IRS-2
levels are at the border of detectability. Interestingly, IL-4–
induced phosphorylation of Stat6 was no longer inhibited
after 22 h of TCR engagement (Fig. 1 A); IRS-2 phosphor-
ylation was barely detectable at this time. Inhibition of
Stat6 phosphorylation was observed within 1 h of TCR li-
gation and reached its maximum at 4 h. IRS-2 phosphory-
lation appeared even more sensitive to inhibition by TCR
ligation, as it was almost fully blocked within 1 h of TCR
engagement (Fig. 1 B).
Inhibition was observed when concentrations of anti-
CD3 as low as 0.08 
 
m
 
g/ml were used to coat culture plates,
and was almost complete at a coating concentration of 0.4
 
m
 
g/ml (Fig. 1 C). If anti-CD28 was omitted, inhibition
was less dramatic although still substantial, particularly for
IRS-2. Anti-CD28 by itself caused no inhibition of IL-4–
mediated phosphorylation of Stat6 or IRS-2 (Fig. 1 D).
Inhibition of IL-4–mediated phosphorylation was ob-
served with a broad range of IL-4 concentrations from 100
U/ml (
 
z
 
50 pg/ml) to 10,000 U/ml (
 
z
 
5 ng/ml). Such
phosphorylation was inhibited even if IL-4 was continu-
ously present during the period of TCR ligation (data not
shown).
Phosphorylation of Stat6 and IRS-2 by IL-4 depends on
proximal events, including the tyrosine phosphorylation of
 
Jak1, Jak3, and IL-4R
 
a
 
 (4, 6–8). The IL-4–stimulated
phosphorylation of these molecules was also inhibited by
6 h of TCR ligation (Fig. 2). As with Stat6, the amount of
these molecules was not diminished by receptor engage-
ment. In T cells that had been stimulated with plate-bound
anti-CD3 and anti-CD28 for 22 h, the phosphorylation of
Jak1, Jak3, and IL-4R
 
a
 
 was similar to or even greater than
in resting T cells. Indeed, amounts of Jak3 and IL-4R
 
a
 
,
but not Jak1, were enhanced after 22 h of TCR ligation.
Thus, TCR ligation inhibited essentially all early IL-4–
mediated signaling events. The simplest explanation would be
that the TCR signal inhibited the capacity of the Jak1 and/
or Jak3 to respond to IL-4–mediated heterodimerization of
Figure 1. TCR ligation transiently downregulates IL-4–induced ty-
rosine phosphorylation of Stat6 and IRS-2 in naive T cells. BALB/c
splenic T cells (A and B) and lymph node CD41 T cells (C and D) were
either stimulated with immobilized anti-CD3 and/or anti-CD28 for vari-
ous times, or not stimulated. Unless otherwise specified, cells were treated
with 3 mg/ml anti-CD3 and/or 3 mg/ml anti-CD28 for 4 h. At the end
of the culture period, some cell samples were challenged with IL-4 (1,000
U/ml) for 20 min. The cells were then lysed, and the lysates were immu-
noprecipitated with either anti-Stat6 or anti–IRS-2. SDS-PAGE was per-
formed and immunoblots with the antiphosphotyrosine antibody 4G10
were carried out. Some filters were stripped and reprobed with anti-Stat6
antibody to check the amount of protein. 
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IL-4R
 
a
 
 and 
 
g
 
c. Mimicking TCR ligation with PMA plus
ionomycin had the same or an even stronger effect on IL-4
signaling; this effect was also transient (data not shown).
 
TCR Ligation Also Inhibits Signaling Events Induced by
Other Cytokines but Not by Insulin-like Growth Factor 1.
 
It
has been reported that in primed T cells, TCR engagement
inhibits IL-2–mediated phosphorylation of Stat5 (35). To
determine if that was true for resting T cells and if TCR li-
gation blocked signaling by other cytokines, we tested re-
sponses to IL-2, IL-6, and IFN-
 
a
 
 in freshly prepared CD4
 
1
 
T cells from BALB/c lymph nodes. 4 h of TCR liga-
tion strikingly inhibited phosphorylation of key substrates
(Stat5b, Stat3, and Jak1, respectively) in response to each of
these cytokines; responses had returned by 22 h of TCR
stimulation (Fig. 3). By contrast, IRS-2 phosphorylation
induced by insulin-like growth factor (IGF)-1 was not in-
hibited by TCR ligation. This is particularly striking in
view of the exquisite sensitivity of the IL-4R’s induction of
IRS-2 phosphorylation to inhibition by TCR ligation.
 
The Induction of an IL-4–responsive Gene Is Also Inhibited
by TCR Engagement.
 
Although very few genes are known
whose expression levels are rapidly upregulated by IL-4 in
naive CD4
 
1
 
 T cells, one that does show this property is the
IL-4R
 
a
 
 chain itself (36, 37). The induction of IL-4R
 
a
 
mRNA expression has been shown to depend on Stat6 ac-
 
tivation. Upon IL-4 stimulation for 4 h, naive CD4
 
1
 
 T
cells express approximately fivefold more IL-4R
 
a
 
 chain
mRNA than cells not stimulated by IL-4 (Fig. 4). By con-
trast, if the cells were stimulated with IL-4 in the presence
of anti-CD3 plus anti-CD28 for 4 h, IL-4R
 
a
 
 chain mRNA
upregulation was completely inhibited, showing that TCR-
mediated inhibition of IL-4 signaling is functional.
In other experiments, we showed that the TCR liga-
tion–mediated inhibition of IL-4R
 
a
 
 mRNA upregulation
was only transient: after TCR ligation for 20 h, IL-4 re-
gained the ability to induce IL-4R
 
a
 
 chain mRNA (data
not shown).
 
Soluble Anti-CD3 or Antigen Also Inhibits IL-4–mediated
Signaling.
 
To determine whether more physiologic modes
of TCR engagement also resulted in transient inhibitions of
IL-4R–mediated signaling, we tested the effect of soluble
anti-CD3 or of antigen in the presence of APCs.
Lymph node cells from BALB/c mice were stimulated
with or without soluble anti-CD3 plus anti-CD28 for 6 h,
and BALB/c spleen cells were used as APCs. Cultured
CD4
 
1
 
 T cells were purified by positive selection on a
MACS (Miltenyi Biotec). The purified T cells were then
stimulated with IL-4 for 20 min. IRS-2 and Stat6 phos-
phorylation was inhibited, and Stat6 expression levels were
unaffected (Fig. 5 A).
Lymph node cells from 5CC7/Rag2
 
2
 
/
 
2
 
 mice were stim-
ulated with PCC peptide in the presence of spleen cells from
B10.A mice as APCs. IRS-2 and Stat6 phosphorylation in
response to IL-4 was inhibited by stimulation with 1 or 100
 
m
 
M peptide for a period of 6 h (Fig. 5 B). Although 100
 
m
 
M PCC may have modestly diminished Stat6 expression,
1 
 
m
 
M had no effect. The regulation of cell surface markers
CD25, CD69, and CD62L by PCC stimulation was also
checked. Both CD25 and CD69 were upregulated, whereas
CD62L was downregulated equally by 1 or 100 
 
m
 
M PCC
stimulation for 6 h as expected, indicating normal cell acti-
vation (data not shown). Jak3 and IL-4R
 
a
 
 chain phosphory-
lation were also checked in these two experiments. Both
were inhibited (data not shown), suggesting that TCR en-
gagement inhibits IL-4 signaling through the same mecha-
Figure 2. IL-4–induced tyrosine phosphorylation of Jak3, Jak1, and
IL-4Ra is also transiently affected by TCR ligation. Lymph node CD41
T cells were stimulated by plate-bound anti-CD3/anti-CD28 for 0, 6, or
22 h in the presence of anti–IL-4 (11B11). They were then washed and
challenged with IL-4 (1,000 U/ml) for 10 min. Lysates were immunopre-
cipitated and immunoblotted, and the blots were then stripped and re-
probed with anti-Jak3, Jak1, and IL-4Ra.
Figure 3. TCR ligation affects signaling by IL-2, IL-6, and IFN-a but
not IGF-1. BALB/c lymph node CD41 T cells were treated with immobi-
lized anti-CD3/anti-CD28 for 0, 4, or 22 h. They were then challenged
with IL-2 (500 U/ml), IFN-a (10 ng/ml), IL-6 (10 ng/ml), or IGF-1 (100
ng/ml) for 20 min. Lysates were immunoprecipitated and immunoblotted.
Figure 4. IL-4 upregulation of IL-4Ra mRNA is blocked by TCR li-
gation. BALB/c lymph node CD41 T cells were treated with or without
IL-4 in the presence or absence of anti-CD3/anti-CD28 for 4 h. At the
end of the culture period, total RNA was prepared and reverse transcrip-
tion PCR for IL-4Ra and b-actin was performed on dilutions of cDNA.
M, marker lane.1129 Zhu et al.
nism whether plate-bound anti-CD3 or a peptide–MHC
complex on a living cell was used for stimulation. These re-
sults imply that inhibition of IL-4 signaling by TCR engage-
ment is a feature of physiologic T cell activation.
Mechanism of Inhibition of IL-4 Signaling by TCR Liga-
tion. Although IL-4Ra expression was little affected by
TCR ligation as judged by Western blot experiments, it is
still possible that IL-4R expression on the cell surface was
diminished. To exclude this possibility, we measured IL-
4R surface expression on CD41 T cells by flow cytometry.
As the level of IL-4Ra expression on naive CD41 T cells is
low (z400 receptors/cell [38]), we used a three-step stain-
ing method for detection. Because of the potential of in-
creasing the staining background when anti-CD3 was used,
we measured IL-4Ra and gc chain expression on naive
5CC7/Rag22/2 cells that had been incubated with T cell–
depleted APCs from B10.A mice but with or without PCC
peptide for 6 h. Neither IL-4Ra nor gc (Fig. 6) expression
was significantly diminished by PCC stimulation. Indeed, a
subset of cells showed increased surface expression of gc as
a result of stimulation with PCC. These results indicate that
the inhibitory effects of TCR ligation are not mediated by
downregulating the expression of IL-4R subunits on the
cell surface.
As IFN-g is known to antagonize IL-4 effects (39) and,
in some systems, to block IL-4–mediated signaling as a re-
sult of suppressor of cytokine signaling (SOCS)1 induction
(40), we tested supernatants of lymph node CD4 T cells
stimulated for 6 h with plate-bound anti-CD3 plus anti-
CD28 for inhibitory activity. Such supernatants failed to
inhibit IL-4–mediated phosphorylation of either Stat6 or
IRS-2 (data no shown). In addition, when freshly purified
naive CD41 T cells were exposed to recombinant IFN-g
directly or after 6 h of TCR engagement, we failed to de-
tect Stat1 phosphorylation (data not shown). When T cells
from IFN-g2/2 mice were studied, the inhibition of IL-4
signaling by TCR ligation was still observed (data not
shown). Thus, it is unlikely that IFN-g plays a role in in-
hibiting IL-4 signaling in T cells stimulated through their
TCR for short periods of time.
To determine whether inhibition of IL-4–mediated sig-
nals by TCR engagement required new protein synthesis,
cycloheximide was added to cultures during TCR engage-
ment. Without new protein synthesis, IRS-2 phosphoryla-
tion was still inhibited as a result of TCR ligation, and
Stat6 phosphorylation was only partially rescued (Fig. 7 A).
However, the interpretation of this experiment is made dif-
ficult by the rather striking effects of cycloheximide treat-
ment on the level of IL-4–mediated phosphorylation of
IRS-2 in T cells that had not been treated with anti-CD3/
anti-CD28.
TCR ligation may induce some inhibitory factors that
enhance the inhibition of Stat6 phosphorylation. The obvi-
ous candidates for such a role are members of the SOCS
family (41–43). However, when SOCS1, SOCS3, and cy-
tokine-inducible SH2 protein 1 (CIS1) mRNA expression
was checked after 4 h of TCR ligation, there was no signif-
icant change in the expression of these molecules (data not
shown). Our results indicate that at least some of the inhib-
itory effects of TCR ligation on IL-4 signaling are inde-
pendent of new protein synthesis.
It has been shown that activation of MEK and extracel-
lular signal–regulated kinase (ERK) blocks IL-6–induced
phosphorylation of Stat3, independent of new protein syn-
thesis and without altering IL-6R expression (44). We
studied the role of the PKC-MAPK pathway triggered by
TCR activation on IL-4–mediated signaling by the addi-
tion of a specific MEK inhibitor. The addition of U0126
(Promega), a potent MEK inhibitor, during the period of
TCR ligation completely rescued the capacity of the cells
to phosphorylate Stat6 and IRS-2 in response to IL-4 (Fig.
7 B). The PKC inhibitor GF109203X (45) partially re-
stored both IRS-2 and Stat6 phosphorylation in response
to IL-4. This strongly suggests that the induction of the
Figure 5. Both soluble anti-CD3/anti-CD28 and antigen treatment of
T cells inhibit IL-4 signaling. BALB/c lymph node cells and spleen cells
(A) or 5CC7/Rag22/2 lymph node cells and T cell–depleted spleen cells
from B10.A mice (B) were pooled. Cultures were stimulated with soluble
anti-CD3 (3 mg/ml) plus anti-CD28 (3 mg/ml) (A) or PCC peptide (1 or
100 mM; B) for 6 h. CD41 T cells were purified by positive selection by
an automatic MACS machine. Purified CD41 T cells were then stimu-
lated with IL-4 (1,000 U/ml) for 20 min and total cell lysates were pre-
pared. Lysates were immunoprecipitated and immunoblotted. Figure 6. IL-4Ra is little affected and gc is upregulated by TCR liga-
tion. Lymph node cells from 5CC7/Rag22/2 mice were cocultured with
T cell–depleted spleen cells from B10.A mice in the presence or absence
of 1 mM PCC for 6 h. Cells were then preincubated with nothing or IL-4
(1 mg/ml) for 30 min on ice. They were then incubated with anti–IL-4R
(M1) (top panels) or with anti–IL-2Rg using a rat Ig of the same isotype
as a control (bottom panels). This was followed by biotin-labeled anti–rat
IgG and streptavidin-PE. FITC-labeled anti-CD4 was added in the last
step and used to gate for CD41 cells.1130 TCR Ligation Inhibits IL-4 Signaling
PKC-MAPK pathway in response to TCR ligation is in-
volved in inhibition of IL-4 signaling.
To determine whether the calcineurin-mediated path-
way contributes to inhibition, two calcineurin inhibitors,
CsA and FK506, were used. Interestingly, these inhibitors
rescued IRS-2 phosphorylation but had limited effects on
Stat6 phosphorylation (Fig. 7 B).
As PMA and the calcium ionophore, ionomycin, can
mimic to some extent the activation of the PKC-MAPK
and calcineurin pathways elicited by TCR ligation, we
tested the ability of these agents, individually or together,
to inhibit IL-4 signaling. Ionomycin caused striking but in-
complete inhibition of IL-4–induced phosphorylation of
IL-4Ra, Jak3, Stat6, and IRS-2 (Fig. 7 C). FK506 and
CsA restored IL-4–mediated phosphorylation in ionomy-
cin-treated cells. Ionomycin-mediated inhibition of IL-4
signaling was not reversed by cycloheximide, suggesting
that calcineurin’s effect may not require nuclear factor of
activated T cells (NFAT)-driven transcription and protein
synthesis.
PMA by itself had only a modest effect on IL-4Ra phos-
phorylation, and none on Jak3 phosphorylation (Fig. 7 D).
However, adding PMA to ionomycin resulted in complete
inhibition of both IL-4Ra and Jak3 phosphorylation. The
PKC inhibitor reversed the capacity of PMA to enhance
the inhibitory activity of ionomycin. These results suggest
that both the PKC-MAPK and the calcineurin pathways
are important for desensitizing the IL-4R.
PMA dramatically activated MAPK (Fig. 7 E), as shown
by the appearance of phosphorylated ERK-1 and ERK-2.
As PMA alone had little effect on IL-4 signaling, this sug-
gests that activation of the MAPK pathway by itself is not
sufficient to desensitize IL-4R. Ionomycin alone was able
to inhibit IL-4 signaling but did not activate MAPK, and
this inhibition was not rescued by the MEK inhibitor (data
not shown), suggesting that the calcineurin pathway may
play a more important role in desensitizing IL-4R when
sustained high intracellular calcium concentrations are
achieved. However, the striking reversal by the MEK in-
hibitor of IL-4R desensitization induced in response to
TCR ligation implies that the magnitude of the calcineurin
effect induced by the TCR is insufficient for independent
inhibition. That is, with TCR ligation, neither pathway
alone is capable of inhibiting IL-4 signaling; both are re-
quired for full suppression.
As IL-4 signaling was only transiently inhibited by TCR
engagement and MAPK plays an important role in this in-
hibition, we measured the degree of MAPK activity at dif-
ferent times after TCR engagement by immunoblotting
with anti–phospho-MAPK. Phospho-MAPK was detect-
Figure 7. The mechanism of desensitizing IL-4R by TCR engagement. Lymph node CD41 T cells from BALB/c mice were pretreated with or with-
out cycloheximide (10 mg /ml), the MEK inhibitor U0126 (100 mM), the PKC inhibitor GF109203X (1 mM), or the calcineurin inhibitors CsA (500
ng/ml) and FK506 (0.1 mM) for 20 min. The cells were treated with or without anti-CD3/anti-CD28 (A and B) or with or without PMA (10 ng/ml)
and/or ionomycin (1 mM; C, D, and E) for 4 h. They were then challenged with or without IL-4 for 20 min. Lysates were immunoprecipitated and im-
munoblotted (A–D). Total lysates were loaded onto SDS-PAGE and immunoblotted with anti–p-ERK. The blot was stripped and reprobed with anti–
ERK-1 (E).1131 Zhu et al.
able at 1 h after TCR ligation, peaked at 4 h, and decreased
at 20 h (Fig. 8 A). Furthermore, as the cells had regained
the ability to respond to cytokines at 20 h, part of the
MAPK activity seen at that time may be elicited by cyto-
kines rather than TCR engagement. Thus, MAPK activity
correlates temporally with TCR-mediated inhibition of
IL-4 signaling.
Although the return of IL-4 signaling at 20 h might be
explained by a diminution in the magnitude of TCR sig-
naling, the cells may have changed their responsiveness to
the inhibitory signal at that time. To explore this possibil-
ity, cells that had been activated by TCR ligation for 20 h
were exposed to PMA plus ionomycin, a treatment that in-
hibits IL-4 signaling in naive T cells independent of TCR.
These 20-h-activated T cells, unlike naive T cells, did not
show inhibition of IL-4–induced Stat6 phosphorylation in
response to PMA plus ionomycin (Fig. 8 B). These results
indicate that the IL-4R became resistant to inhibition after
20 h of TCR engagement. Although the mechanism un-
derlying resistance is unclear, the upregulation of IL-4R,
Jak3, and Stat6 expression (Figs. 1, 2, and 8 B) may con-
tribute to this resistance.
Possible Biological Importance. As functional IL-4R but
not IL-12R is expressed on naive CD41 T cells (33, 34,
36–38), one might anticipate that polarization to the Th2
pathway would be favored when naive CD4 cells are
primed in the presence of both IL-4 and IL-12. However,
as TCR ligation transiently desensitizes IL-4R, this might
serve to redress the balance in priming for a cytokine-pro-
ducing phenotype. We wished to determine the dynamics
of acquisition of competence to respond to IL-12 on the
part of naive CD4 T cells and of their reestablishment of
responsiveness to IL-4 in T cells that had been stimulated
through their TCR. Naive CD41 T cells were primed
with anti-CD3 plus anti-CD28 in the presence of both IL-4
and IL-12 for various times, and Stat6 and Stat4 phos-
phorylation was checked. Although Stat6 phosphorylation
was induced by IL-4 in naive CD41 T cells, TCR ligation
resulted in its inhibition; Stat6 phosphorylation did not re-
turn to normal until 12 h after initiation of TCR ligation
(Fig. 9). By contrast, IL-12 did not induce Stat4 phosphor-
ylation in resting, naive T cells; however, by 8 h of T cell
ligation, Stat4 phosphorylation was induced by IL-12, and
the degree of IL-12–mediated Stat4 phosphorylation did
not further increase over times up to 20 h. Thus, the tran-
sient inhibition of IL-4 signaling as a result of TCR ligation
may have ablated any potential advantage IL-4 might have,
and gave IL-12 a greater opportunity to drive naive CD41
T cells to polarize to Th1 cells.
For this observation to be of any significance in the po-
larization process, it would be important that the early cy-
tokine environment have a substantial role to play in the
decision of CD4 T cells to differentiate into Th1 or Th2
cells. To test this, naive CD41 T cells were primed in the
presence of IL-4 or anti–IL-4 and IL-12 or anti–IL-12 dur-
ing the initial 20 h of culture; all of the cells were then
stimulated in the presence of IL-4 and IL-12 for an addi-
tional 3 d. After another 3 d in IL-2 medium, the cells
were stimulated with immobilized anti-CD3 plus anti-
CD28, and the proportion of IL-4 and of IFN-g–produc-
ing cells was measured (Fig. 10). Priming for the initial 20 h
in the presence of IL-4 and anti–IL-12 suppresses priming
for IFN-g compared with priming in the presence of anti–
IL-4 and anti–IL-12, whereas priming in the presence of
IL-12 and anti–IL-4 enhances priming for IFN-g com-
pared with priming with anti–IL-4 and anti–IL-12. Cells
that were primed with both IL-4 and IL-12 were similar to
cells primed with anti–IL-4 and anti–IL-12. In a sense, it
could be said that IL-12 strikingly reverses the inhibitory
effect of IL-4 on early priming for IFN-g production. This
striking effect of transient exposure to different combina-
tions of IL-4 and IL-12 in the first 20 h of culture is even
Figure 8. Possible mechanism of IL-4 signaling return. (A) A time
course of MAPK activity induced by TCR ligation. Lymph node CD41
T cells from BALB/c mice were pretreated with or without the MEK in-
hibitor U0126 (100 mM) for 20 min. The cells were then treated with
anti-CD3/anti-CD28 for 0, 1, 4, and 20 h. Total lysates were made and
loaded to SDS-PAGE. Immunoblots with anti–p-ERK was carried out.
The blot was then stripped and reprobed with anti–ERK-1. (B) Lymph
node naive CD41 T cells were activated by anti-CD3/anti-CD28 in the
presence of 11B11 for 20 h, and the cells were then washed and stimu-
lated with fresh anti-CD3/anti-CD28 or PMA plus ionomycin for an ad-
ditional 4 h. They were then challenged with or without IL-4 for 20 min.
The freshly isolated naive CD41 T cells were treated in the same way as a
control. Lysates were immunoprecipitated and immunoblotted. The blot
was stripped and reprobed with anti-Stat6.
Figure 9. Dynamics of IL-4 signaling and IL-12 signaling in the early
stage of T cell activation. CD41 lymph node T cells from BALB/c mice
were treated with anti-CD3/anti-CD28 for 0, 4, 8, 12, 16, or 20 h in the
presence of both IL-4 (1,000 U/ml) and IL-12 (10 ng/ml). Lysates were
immunoprecipitated and immunoblotted.1132 TCR Ligation Inhibits IL-4 Signaling
more remarkable when one considers that the cells are in-
sensitive to IL-4 for z12 h of this period and to IL-12 for
z8 h. Thus, even a very brief exposure to a given cytokine
environment early in the period of stimulation strikingly
effects the polarization of cells despite the fact that they are
cultured under identical conditions for the bulk of the
priming period. These results strongly suggest that early cy-
tokine-mediated signals received by CD4 T cells play an
important role in their decision to polarize into the Th1 or
Th2 phenotype. This emphasizes the potential importance
of the TCR-mediated desensitization events that limit re-
sponsiveness of naive T cells to IL-4 and other type I and
type II cytokines.
Discussion
In this study, it was shown that IL-4–mediated signals
were strikingly but transiently inhibited by TCR engage-
ment of naive T cells. This inhibition involved triggering
of both the PKC-MAPK and calcineurin pathways. It has
recently been reported by Ivashkiv and colleagues that the
IL-2 signal was inhibited by TCR engagement in preacti-
vated T cells and the inhibition was mediated by the PKC-
MAPK pathway (35). We have also checked the IL-4 sig-
nal in activated cells and observed results quite similar to
those described above for naive T cells (data not shown). In
addition, we found that the IL-2 signal was also inhibited
by TCR engagement in naive T cells. McMahon and col-
leagues have shown that sustained activation of the Raf–
MEK-ERK pathway elicited cytokine unresponsiveness in
T cells (46). These results are consistent in indicating that
MAPK plays an important role in the cross-talk between
TCR and cytokine signals. Our data further show that al-
though MAPK activation is necessary, it is not sufficient to
inhibit the IL-4 signal (Fig. 7, C and D).
Our experiments reveal some new and potentially very
critical points. One is that the cytokine signal returns after
TCR ligation for a certain period of time. The mechanism
through which sensitivity to IL-4 is regained is unclear. IL-4
itself did not contribute to the reacquisition of sensitivity,
as the addition of anti–IL-4 antibody (11B11) during TCR
engagement did not delay the return of sensitivity (Fig. 2).
Downregulation of cell surface TCR and CD3 expression
by TCR ligation could be an explanation for the return of
sensitivity to IL-4 and other cytokines (35, 47). As MAPK
plays a critical role in this inhibition, the return of the cy-
tokine signal may simply be due to a decrease of MAPK ac-
tivity (Fig. 8 A). Alternatively, TCR ligation may cause the
expression of a new protein(s) that reverses the inhibition
caused by the TCR signal, as the cells activated by TCR li-
gation for 20 h did not show the inhibition of IL-4 signal
by PMA plus ionomycin treatment (Fig. 8 B). We ob-
served that IL-4Ra, Jak3, and Stat6 expression levels were
induced by TCR engagement; such increased expression
may offer a partial explanation of returned sensitivity (Figs.
1, 2, and 8 B). Clarifying the mechanism of signal return
will be very interesting and potentially very important. In-
deed, if cells lose the capacity to overcome transient inhibi-
tion and thus the cytokine signal does not return, they may
become anergic.
Another new finding in our experiments is that the cal-
cineurin pathway can play a major role in inhibiting IL-4
signaling. Indeed, ionomycin treatment by itself inhibits
phosphorylation of IL-4Ra, Jak3, Stat6, and IRS-2 phos-
phorylation. FK506 rescues this inhibition and the inhibi-
tion of IRS-2 phosphorylation mediated by TCR engage-
ment. CsA also reverses inhibition, but it was less effective.
Calcineurin plays a major role in regulating NFAT activity,
which in turn is critical for the transcription of cytokine
genes (48). Nonetheless, the finding that an inhibitor of
protein synthesis failed to reverse the effects of ionomycin
suggests that inhibition of calcineurin blocks IL-4 signaling
through an NFAT-independent pathway.
IL-4Ra as well as gc are expressed on naive CD41 T
cells, so such cells can immediately respond to IL-4 (36–
38). By contrast, IL-12Rb2 is not expressed on naive cells;
such cells are unresponsive to IL-12. However, IL-12Rb2
can be induced by TCR ligation (33, 34) and as these cells
already express IL-12Rb1, they gain responsiveness to IL-
12. As IL-4 and IL-12 are the key cytokines in determining
the commitment of naive T cells to the Th2 or Th1 phe-
notype, the differential expression and/or sensitivity of
their receptors could be an important factor in determining
the T cell phenotype polarization (1). This could be partic-
ularly important because IL-4 not only commits cells to be-
come Th2 cells but also suppresses their capacity to develop
into IFN-g producers (1, 32).
Figure 10. The cytokine environment early in the course of T cell ac-
tivation affects Th1/Th2 polarization. 106 naive CD41 BALB/c T cells
were cocultured with 107 irradiated T cell–depleted spleen cells in the
presence of anti-CD3 (3 mg /ml), anti-CD28 (3 mg/ml), IL-2 (10 U/ml),
and different combinations of anti–IL-4 (11B11, 10 mg/ml), IL-4 (1,000
U/ml), anti–IL-12 (10 mg/ml), and IL-12 (10 ng/ml) for 20 h. Cells were
then washed and stimulated with anti-CD3, anti-CD28, IL-2, IL-4, and
IL-12 for an additional 3 d. After incubation in IL-2 for an additional 3 d,
cells were restimulated with plate-bound anti-CD3 and anti-CD28 for 6 h;
monensin (2 mM) was present during the last 4 h. Cells were harvested
and stained for intracellular IFN-g and IL-4 expression. The data are rep-
resentative of three independent experiments.1133 Zhu et al.
Our data also demonstrated that the presence of IL-4 un-
opposed by IL-12 during the first 20 h of culture strikingly
changed the ratio of IL-4 to IFN-g producers that devel-
oped upon subsequent culture in the presence of IL-4 and
IL-12 for 3 d (Fig. 10). This skewing in the Th1/Th2 ratio
was conserved even after a second round of priming (data
not shown). This indicates that the early signals received by
naive T cells play a critical role in determining the cells’
differentiation fate. Indeed, the IL-4R was desensitized for
12 h, so the cells received effective IL-4 signals for only 8 h
during the first 20 h of T cell activation. As the cells do not
respond to IL-12 during the first 8 h, conditions involving
IL-4 and anti–IL-12 for the first 20 h of culture may mimic
the situation that would pertain if the IL-4R had not been
desensitized by TCR ligation, providing IL-4 with an 8-h
advantage over IL-12. Thus, one potential reason for regu-
lating the IL-4R to make it insensitive for a period of z12 h
after TCR ligation is to overcome the advantage IL-4
would have in the IL-4/IL-12 competition in view of the
absence of functional IL-12R from resting T cells.
The opportunity to regulate the relative degree of re-
sponsiveness of the IL-4 and the IL-12R, one by control-
ling its desensitization and the other by controlling its in-
duction, provides an additional mechanism through which
the system can “tune” the degree of priming to the Th2
and Th1 phenotypes and thus the quality of T cell re-
sponses can be controlled. Such relatively fine quantitative
adjustments may prove to have substantial real world signif-
icance. Almost certainly, in physiologic priming both in-
ducers will be present to some degree, and the outcome
will be determined both by their relative concentrations
and by the relative degree of responsiveness of the cells to
the two stimulants.
Balancing Th1/Th2 differentiation may not be the only
or even the major consequence of transiently modulating
cytokine signaling through TCR engagement, as the sig-
naling of a broad range of cytokines is inhibited by TCR
ligation. Indeed, as so many of the functions of cytokine
receptors depend on costimulation through the TCR, ana-
lyzing the integration of TCR- and cytokine-mediated sig-
nal transduction will have substantial importance in efforts
to develop and understand of the dynamics of cytokine-
mediated processes.
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